Mitsubishi Tanabe Pharma Corporation

Ritsuo Imashiro

Tetsu Nakane

Hidekazu Tsujishima

Atsushi Sato

Akira Kubo

Norimitsu Hayashi

Osamu Sakurai

Hiroaki Sawamoto

Kenji Morokuma

Kunio Saruta

Hiroaki Shitama

Hidetaka Miyoshi

Akihito Ogasawara

Hajime Hiramatsu

Tatsuo Nakajima

Takashi Goi

Hiroaki Sakurai

Yasuo Yamamoto

Yasunori Moritani

Chihiro Toshikawa

Kouichi Tanimoto

The present invention relates to a novel imidazole compound or a pharmaceutically acceptable salt thereof having a melanocortin receptor agonistic activity, and medical use thereof. The present invention relates to an imidazole compound represented by general formula [I] [wherein: Ring A represents an optionally substituted aryl group or the like; Rrepresents a hydrogen atom, an optionally substituted alkyl group, or the like; Rrepresents a hydrogen atom, a halogen atom, or the like; and Rrepresents an optionally substituted alkyl group] or a pharmaceutically acceptable salt thereof.

Substituted imidazoles as melanocortin receptor agonists

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof. 

Continuous arycyclic compound

The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein 

Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity

The present invention relates to a compound of the formula [I]: wherein Gis an alkyl which is substituted by a halogen atom or an alkoxy, or a group of the formula: wherein ring B is benzene ring which may be substituted, etc., Q1 and Q2 may be the same or different, and each is hydrogen atom, a halogen atom or an alkyl, n is 0, 1, 2, 3 or 4, Ris hydrogen atom, an alkyl which may be substituted, a cycloalkyl which may be substituted, a phenyl which may be substituted, etc., Z, Z, Zand Zmay be the same or different, and each is CH or N, provided that 3 or more of Z, Z, Zand Zshould not be N at the same time, Gis hydrogen atom, &#x2014;NRR, &#x2014;OR, etc., where Rto Reach is independently hydrogen atom, an alkyl which may be substituted, an alkenyl, an alkynyl, etc., or a pharmaceutically acceptable salt thereof.

4-imidazolin-2-one compounds

The present invention relates to a compound of the formula [I]:  

Growing community of inventors

Osaka, Japan

Ritsuo Imashiro